Keratitis - Pipeline Review, H2 2011 by GlobalMarketsDirect

VIEWS: 0 PAGES: 36

More Info
									Keratitis – Pipeline Review, H2 2011




                                Keratitis - Pipeline Review, H2 2011
                                                                                          Reference Code: GMDHC1538IDB

                                                                                          Publication Date: November 2011




Keratitis – Pipeline Review, H2 2011                                                                          GMDHC1538IDB / Pub November 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                Page(1)
Keratitis – Pipeline Review, H2 2011



Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 3
      List of Figures .................................................................................................................................................................................................... 4
Introduction .............................................................................................................................................................................................................. 5
      Global Markets Direct Report Coverage ............................................................................................................................................................. 5
Keratitis Overview .................................................................................................................................................................................................... 6
Therapeutics Development ....................................................................................................................................................................................... 7
      An Overview of Pipeline Products for Keratitis.................................................................................................................................................... 7
Keratitis Therapeutics under Development by Companies ........................................................................................................................................ 9
Keratitis Therapeutics under Investigation by Universities/Institutes ........................................................................................................................10
Late Stage Products ................................................................................................................................................................................................11
      Comparative Analysis .......................................................................................................................................................................................11
Mid Clinical Stage Products .....................................................................................................................................................................................12
      Comparative Analysis .......................................................................................................................................................................................12
Early Clinical Stage Products ..................................................................................................................................................................................13
      Comparative Analysis .......................................................................................................................................................................................13
Pre-Clinical Stage Products .....................................................................................................................................................................................14
      Comparative Analysis .......................................................................................................................................................................................14
Keratitis Therapeutics - Products under Development by Companies ......................................................................................................................15
Keratitis Therapeutics - Products under Investigation by Universities/Institutes .......................................................................................................16
Companies Involved in Keratitis Therapeutics Development ....................................................................................................................................17
      Menarini Group .................................................................................................................................................................................................17
      RegeneRx Biopharmaceuticals, Inc...................................................................................................................................................................17
      Sirnaomics, Inc. ................................................................................................................................................................................................18
Keratitis - Therapeutics Assessment........................................................................................................................................................................19
      Assessment by Monotherapy Products .............................................................................................................................................................19
      Assessment by Combination Products ..............................................................................................................................................................20
      Assessment by Route of Administration ............................................................................................................................................................21
      Assessment by Molecule Type ..........................................................................................................................................................................23
Drug Profiles ...........................................................................................................................................................................................................25
      Brivudin - Drug Profile .......................................................................................................................................................................................25
            Product Description ....................................................................................................................................................................................25
            Mechanism of Action...................................................................................................................................................................................25
            R&D Progress .............................................................................................................................................................................................25
      RGN-259 - Drug Profile .....................................................................................................................................................................................26
            Product Description ....................................................................................................................................................................................26
            Mechanism of Action...................................................................................................................................................................................26
            R&D Progress .............................................................................................................................................................................................26
      Prednisolone Phosphate + Acyclovir - Drug Profile ...........................................................................................................................................27
            Product Description ....................................................................................................................................................................................27
            Mechanism of Action...................................................................................................................................................................................27
            R&D Progress .............................................................................................................................................................................................27
      HO/05/09 - Drug Profile .....................................................................................................................................................................................29
            Product Description .......................................................................................................................
								
To top